Endocrine Abstracts

Introduction: The NETTER 1 trial resulted in markedly longer progression-free survival (PFS), with preliminary evidence of an overall survival benefit. We report the results of PFS and safety of (177Lu)-DOTATATE in patients treated in our hospital between 2014 and 2016.Methods: Transversal and descriptive study of seven patients with advanced, progressive, somatostatin receptor-positive tumors who had received previous treatments. All of them were treate...

Introduction: The NETTER 1 trial resulted in markedly longer progression-free survival (PFS), with preliminary evidence of an overall survival benefit. We report the results of PFS and safety of (177Lu)-DOTATATE in patients treated in our hospital between 2014 and 2017.Methods: Transversal and descriptive study of 22 patients with advanced, progressive, somatostatin receptor-positive tumors who had received previous treatments. All of them were treated w...